Identification of 3-acetyl-2-aminoquinolin-4-one as a novel, nonpeptidic scaffold for specific calpain inhibitory activity

Journal of Medicinal Chemistry

Volumn 52, Issue 9, 2009, Pages 3093-3097

  Kang, Da Hye ^a   Jun, Kyu Yeon ^a   Jin, Pyo Lee ^b   Chwang, Siek Pak ^c   Na, Younghwa ^d   Kwon, Youngjoo ^a  

^a Ewha Womans University   (South Korea)

^b Chungnam National University   (South Korea)

^c Korea Research Institute of Chemical Technology   (South Korea)

^d Catholic University of Daegu   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIBROMOPHENYL; 3 ACETYL 2 AMINOQUINOLIN 4 ONE; [1 [(1 FORMYL 2 PHENYLETHYL)CARBAMOYL] 2 METHYLPROPYL]CARBAMIC ACID BENZYL ESTER; CALPAIN; CALPASTATIN; UNCLASSIFIED DRUG;

ARTICLE; DRUG INHIBITION; DRUG STRUCTURE; FLUOROMETRY; STRUCTURE ACTIVITY RELATION;

4-QUINOLONES; AMINOQUINOLINES; CALPAIN; CATALYTIC DOMAIN; DRUG DESIGN; FLUOROMETRY; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, MOLECULAR; PEPTIDES; SMALL MOLECULE LIBRARIES; SUBSTRATE SPECIFICITY;

EID: 65649103812     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm8014734     Document Type: Article

References (29)

1. (a) Saito, K.; Elce, J. S.; Hamos, J. E.; Nixon, R. A. Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 2628-2632. (Pubitemid 23113469)
2. (b) Sato, K.; Kawashima, S. Calpain function in the modulation of signal transduction molecules. Biol. Chem. 2001, 382, 743-751. (Pubitemid 32631711)
3. Croall, D. E.; DeMartino, G. N. Calcium-activated neutral protease (calpain) system: structure, function, and regulation. Physiol. Rev. 1991, 71, 813-847.
4. (a) Mellgren, R. L. Interaction of human erythrocyte multicatalytic proteinase with polycations. Biochim. Biophys. 1990, 1040, 28-34. (Pubitemid 20230001)
5. (b) Saido, T. C.; Shibata, M.; Takenawa, T.; Murofushi, H.; Suzuki, K. Positive regulation of mu-calpain action by polyphosphoinositides. J. Biol. Chem. 1992, 267, 24585-24590.
6. (c) Salamino, F.; De Tullio, R.; Mengotti, P.; Viotti, P. L.; Melloni, E.; Pontremoli, S. Site-directed activation of calpain is promoted by a membrane-associated natural activator protein. Biochem. J. 1993, 290, 191-197. (Pubitemid 23081219)
7. Baudry, M.; DuBrin, R.; Beasley, L.; Leon, M.; Lynch, G. Low levels of calpain activity in Chiroptera brain: implications for mechanisms of aging. Neurobiol. Aging 1986, 255-258. (Pubitemid 17172366)
8. (a) Bartus, R. T. The calpain hypothesis of neurodegeneration: evidence for a common cytotoxic pathway. Neuroscientist 1997, 3, 314-327. (Pubitemid 127533634)
9. (b) Chen, M.; He, H.; Zhan, S.; Krajewski, S.; Reed, J. C.; Gottlieb, R. A. Bid is cleaved by calpain to an active fragment in vitro and during myocardial ischemia/reperfusion. J. Biol. Chem. 2001, 276, 30724-30728. (Pubitemid 37384928)
10. Mathews, P. M.; Jiang, Y.; Schmidt, S. D.; Grbovic, O. M.; Mercken, M.; Nixon, R. A. Calpain activity regulates the cell surface distribution of amyloid precursor protein. Inhibition of calpains enhances endosomal generation of beta-cleaved C-terminal APP fragments. J. Biol. Chem. 2002, 277, 36415-36424.
11. Lee, M. S.; Kwon, Y. T.; Li, M.; Peng, J.; Friedlander, R. M.; Tsai, L. H. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature (London) 2000, 405, 360-364. (Pubitemid 30337070)
12. Camins, A.; Verdaguer, E.; Folch, J.; Canudas, A. M.; Pallàs, M. The role of CDK5/P25 formation/inhibition in neurodegeneration. Drug News Perspect. 2006, 19, 453-460. (Pubitemid 46050819)
13. Shirasaki, Y.; Nakamura, M.; Yamaguchi, M.; Miyashita, H.; Sakai, O.; Inoue, J. Exploration of orally available calpain inhibitors 2: peptidyl hemiacetal derivatives. J. Med. Chem. 2006, 49, 3926-3932. (Pubitemid 43967889)
14. Zeng, Y.; Li, Q.; Hanzlik, R. P.; Aubé, J. Synthesis of a small library of diketopiperazines as potential inhibitors of calpain. Bioorg. Med. Chem. Lett. 2005, 15, 3034-3038. (Pubitemid 40755192)
15. (a) Li, Z.; Ortega-Vilain, A.-C.; Patil, G. S.; Chu, D.-L.; Foreman, J. E.; Eveleth, D. D.; Powers, J. C. Novel peptidyl alpha-keto amide inhibitors of calpains and other cysteine proteases. J. Med. Chem. 1996, 39, 4089-4098. (Pubitemid 26327445)
16. (b) Donkor, I. O.; Assefa, H.; Liu, J. Structural basis for the potent calpain inhibitory activity of peptidyl alpha-ketoacids. J. Med. Chem. 2008, 51, 4346-4350.
17. Cuerrier, D.; Moldoveanu, T.; Campbell, R. L.; Kelly, J.; Yoruk, B.; Verhelst, S. H.; Greenbaum, D.; Bogyo, M.; Davies, P. L. Development of calpain-specific inactivators by screening of positional-scanning epoxide libraries. J. Biol. Chem. 2007, 282, 9600-9611.
18. Graybill, T. L.; Dolle, R. E.; Osifo, I. K.; Schmidt, S. J.; Gregory, J. S.; Harris, A. L.; Miller, M. S. Inhibition of human erythrocyte calpain I by novel quinolinecarboxamides. Bioorg. Med. Chem. Lett. 1995, 5, 387-392.
19. Mittoo, S.; Sundstrom, L. E.; Bradley, M. Synthesis and evaluation of fluorescent probes for the detection of calpain activity. Anal. Biochem. 2003, 319, 234-238. (Pubitemid 36842731)
20. Harris, A. S.; Morrow, J. S. Proteolytic processing of human brain alpha spectrin (fodrin): identification of a hypersensitive site. J. Neurosci. 1988, 8, 2640-2651. (Pubitemid 18195235)
21. Hwang, B. H.; Park, S. H.; Choi, E. B.; Pak, C. S.; Lee, H. K. A methodology for the synthesis of highly functionalized 2- and 4-aminoquinolin derivatives. Tetrahedron 2008, 64, 6698-6704.
22. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated docking using a Lamarckian genetic algorithm and empirical binding free energy function. J. Comput. Chem. 1998, 19, 1639-1662. (Pubitemid 128590223)
23. (a) Moldoveanu, T.; Campbell, R. L.; Cuerrier, D.; Davies, P. L. Crystal structures of calpain-E64 and -leupeptin inhibitor complexes reveal mobile loops gating the active site. J. Mol. Biol. 2004, 343, 1313-1326. (Pubitemid 39387829)
24. (b) Li, Q.; Hanzlik, R. P.; Weaver, R. F.; Schonbrunn, E. Molecular mode of action of a covalently inhibiting peptidomimetic on the human calpain protease core. Biochemistry 2006, 45, 701-708. (Pubitemid 43122235)
25. (c) Cuerrier, D.; Moldoveanu, T.; Inoue, J.; Davies, P. L.; Campbell, R. L. Calpain inhibition by alpha-ketoamide and cyclic hemiacetal inhibitors revealed by X-ray crystallography. Biochemistry 2006, 45, 7446-7452. (Pubitemid 43894938)
26. (a) Mueller-Steiner, S.; Zhou, Y.; Arai, H.; Roberson, E. D.; Sun, B.; Chen, J.; Wang, X.; Yu, G.; Esposito, L.; Mucke, L.; Gan, L. Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease. Neuron 2006, 51, 703-714. (Pubitemid 44374903)
27. (b) Boland, B.; Campbell, V. A β-mediated activation of the apoptotic cascade in cultured cortical neurones: a role for cathepsin-L. Neurobiol. Aging 2004, 25, 83-91. (Pubitemid 37522196)
28. (c) Yasuda, Y.; Kageyama, T.; Akamine, A.; Shibata, M.; Kominami, E.; Uchiyama, Y.; Yamamoto, K. Characterization of new fluorogenic substrates for the rapid and sensitive assay of cathepsin E and cathepsin D. J. Biochem. (Tokyo) 1999, 125, 1137-1143. (Pubitemid 29332996)
29. Knight, C. G.; Barrett, A. J. Interaction of human cathepsin D with the inhibitor pepstatin. Biochem. J. 1976, 155, 117-125.